Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development

Journal of Clinical Pharmacology

Volumn 40, Issue 12 II, 2000, Pages 1419-1427

  Colburn, W A ^a  

^a MDS Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DRUG;

CONFERENCE PAPER; DISEASE MARKER; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; MODEL; OUTCOMES RESEARCH; PHARMACODYNAMICS; PHARMACOKINETICS; PREDICTION; TREATMENT OUTCOME; VALIDATION PROCESS;

BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG THERAPY; FORECASTING; HUMANS; PHARMACOKINETICS; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 0033730474     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Surrogate endpoints in clinical trials: Definition and operational criteria
2. Surrogate markers and clinical pharmacology
3. Surrogate biochemical markers: Precise measurement for strategic drugs and biologics development
4. The validity of surrogate markers in rheumatic disease
5. Measurement validity in physical therapy research
6. Commentary: Efficacy measures: Surrogates or clinical outcomes?
7. Decision making during NME development
8. The contribution of clinical pharmacology surrogates and models to drug development: A critical appraisal
9. Selecting and validating biologic markers for drug development
10. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
11. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease
12. Pharmacokinetics and pharmacodynamics following intravenous bolus and infusion doses of AC137 (25,28,29 tripro-amylin, human) to insulin dependent diabetics
13. Application of clinical assays for pharmacodynamic measurement of coagulation and fibrinolysis markers